Bio

Professional Education


  • Doctor of Philosophy, Technische Universitat Munchen (2012)
  • Diplom, Universitat Erlangen Nurnberg (2008)

Stanford Advisors


Publications

All Publications


  • Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer MOLECULAR CANCER THERAPEUTICS Gruener, B. M., Winkelmann, I., Feuchtinger, A., Sun, N., Balluff, B., Teichmann, N., Herner, A., Kalideris, E., Steiger, K., Braren, R., Aichler, M., Esposito, I., Schmid, R. M., Walch, A., Siveke, J. T. 2016; 15 (5): 1145-1152

    Abstract

    Pancreatic ductal adenocarcinoma (PDAC) is likely the most aggressive and therapy-resistant of all cancers. The aim of this study was to investigate the emerging technology of matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) as a powerful tool to study drug delivery and spatial tissue distribution in PDAC. We utilized an established genetically engineered mouse model of spontaneous PDAC to examine the distribution of the small-molecule inhibitor erlotinib in healthy pancreas and PDAC. MALDI IMS was utilized on sections of single-dose or long-term-treated mice to measure drug tissue distribution. Histologic and statistical analyses were performed to correlate morphology, drug distribution, and survival. We found that erlotinib levels were significantly lower in PDAC compared with healthy tissue (P = 0.0078). Survival of long-term-treated mice did not correlate with overall levels of erlotinib or with overall histologic tumor grade but did correlate both with the percentage of atypical glands in the cancer (P = 0.021, rs = 0.59) and the level of erlotinib in those atypical glands (P = 0.019, rs = 0.60). The results of this pilot study present MALDI IMS as a reliable technology to study drug delivery and spatial distribution of compounds in a preclinical setting and support drug imaging-based translational approaches. Mol Cancer Ther; 15(5); 1145-52. ©2016 AACR.

    View details for DOI 10.1158/1535-7163.MCT-15-0165

    View details for Web of Science ID 000375857400035

    View details for PubMedID 26823494

  • Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing GENES & DEVELOPMENT Chiou, S., Winters, I. P., Wang, J., Naranjo, S., Dudgeon, C., Tamburini, F. B., Brady, J. J., Yang, D., Gruener, B. M., Chuang, C., Caswell, D. R., Zeng, H., Chu, P., Kim, G. E., Carpizo, D. R., Kim, S. K., Winslow, M. M. 2015; 29 (14): 1576-1585

    Abstract

    Pancreatic ductal adenocarcinoma (PDAC) is a genomically diverse, prevalent, and almost invariably fatal malignancy. Although conventional genetically engineered mouse models of human PDAC have been instrumental in understanding pancreatic cancer development, these models are much too labor-intensive, expensive, and slow to perform the extensive molecular analyses needed to adequately understand this disease. Here we demonstrate that retrograde pancreatic ductal injection of either adenoviral-Cre or lentiviral-Cre vectors allows titratable initiation of pancreatic neoplasias that progress into invasive and metastatic PDAC. To enable in vivo CRISPR/Cas9-mediated gene inactivation in the pancreas, we generated a Cre-regulated Cas9 allele and lentiviral vectors that express Cre and a single-guide RNA. CRISPR-mediated targeting of Lkb1 in combination with oncogenic Kras expression led to selection for inactivating genomic alterations, absence of Lkb1 protein, and rapid tumor growth that phenocopied Cre-mediated genetic deletion of Lkb1. This method will transform our ability to rapidly interrogate gene function during the development of this recalcitrant cancer.

    View details for DOI 10.1101/gad.264861.115

    View details for Web of Science ID 000358596300010

    View details for PubMedID 26178787

  • EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis CANCER CELL Ardito, C. M., Gruener, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P. K., DelGiorno, K. E., Carpenter, E. S., Halbrook, C. J., Hall, J. C., Pal, D., Briel, T., Herner, A., Trajkovic-Arsic, M., Sipos, B., Liou, G., Storz, P., Murray, N. R., Threadgill, D. W., Sibilia, M., Washington, M. K., Wilson, C. L., Schmid, R. M., Raines, E. W., Crawford, H. C., Siveke, J. T. 2012; 22 (3): 304-317

    Abstract

    Initiation of pancreatic ductal adenocarcinoma (PDA) is definitively linked to activating mutations in the KRAS oncogene. However, PDA mouse models show that mutant Kras expression early in development gives rise to a normal pancreas, with tumors forming only after a long latency or pancreatitis induction. Here, we show that oncogenic KRAS upregulates endogenous EGFR expression and activation, the latter being dependent on the EGFR ligand sheddase, ADAM17. Genetic ablation or pharmacological inhibition of EGFR or ADAM17 effectively eliminates KRAS-driven tumorigenesis in vivo. Without EGFR activity, active RAS levels are not sufficient to induce robust MEK/ERK activity, a requirement for epithelial transformation.

    View details for DOI 10.1016/j.ccr.2012.07.024

    View details for Web of Science ID 000308735400007

Footer Links:

Stanford Medicine Resources: